Qiagen

News Qiagen

  • QIAGEN announces broad agreement with Astellas Pharma to develop companion diagnostics

    QIAGEN N.V.  announced a master collaboration agreement with Astellas Pharma Inc. to develop and commercialize companion diagnostics paired with Astellas drugs for use in cancer and other diseases. The scope of the agreement is not restricted to certain sample types, platforms, indications or biomar more

  • QIAGEN adds promising genomic biomarkers to pipeline

    QIAGEN N.V. announced it has acquired an exclusive global license to the biomarker SF3B1 from the University of Tokyo. SF3B1 is believed to play a critical role in the prognosis of patients with myelodysplastic syndromes (MDS), a group of hematological cancers in which bone marrow does not produce e more

  • analytica presents biotechnology highlights

    From molecular-biology techniques to forensic DNA analysis: from April 17 – 20 analytica features in-depth information about the latest methods and techniques in laboratory technology, analysis and biotechnology. One of the five halls, hall A3, is devoted entirely to the biotech industry. The topic more

All news on qiagen

White papers Qiagen

  • LOOXSTER® concentrates bacterial DNA

    Detection of the bacterial content of a specific sample, irrelevant from its source, is not as straightforward as it seems. In clinical microbiology laboratories, the gold standard method for the detection of pathogens in patients suspected of systemic infections is the blood culture. However, this technique is known to have many drawbacks especially with regard to patient's antibiotics treatment, low abundance and non-cultivable organisms. Moreover, it takes usually 3 to 5 days to obtain a result from blood culture which is too late to initiate proper antibiotic therapy. Amplification-based methods such as PCR allow results in a more rapid fashion. However, their sensitivity, to date, are no better, and sometimes worse, than culture-based methods. more

  • LightCycler® 480 System: High-throughput Gene Expression and Genotyping Analysis - A Performance Study

    The LightCycler® 480 System is a novel platform for rapid gene expression and melting curve-based genotyping for medium- and high-throughput. In order to assess the performance and ease-of-use of the complete LightCycler® 480 System (instrument, software, and reagents) in an academic laboratory setting we scheduled a high-throughput project including gene expression (39 targets in 88 samples = 3,400 expression values) as well as genotyping applications (3,808 genotypes; 14 SNPs in 288 samples). The project, involving five technicians and two graduate students, was accomplished within 15 working days. more

Websites Qiagen

GENEART - Excellence in DNA Engineering and Processing: Gene Synthesis, Directed Evolution, Plasmid

HOME ENGLISH JAPANESE LOGIN   |   SEARCH   |   SITEMAP   |   LEGAL   |   PRIVACY   |   GENERAL TERMS PRODUCTS + SERVICES CUSTOMER PORTAL REFERENCES Customers Publications Customer Statements EVENTS + PRESS COMPANY INVESTOR RELATIONS CONTACT Europe & Asia phone: +49 (0)941 942 76-100 fax:        +49 more

MolYsis – Targeted Pathogen DNA Isolation

 Skip to Content Jump to Main Navigation and Login Jump to additional Information Search, View and Navigation Home Diagnostic Research Products MolYsis – Targeted Pathogen DNA Isolation Search About Molzym R&D Distributors Imprint Disclaimer Contact   MAIN MENU Home Diagnostic Research Products Mol more

CYTOO cell architects Company

Vocation NewsRoom Career s Partners' wall Contact Vocation CYTOO focuses on innovative products for the life science research market with an emphasis in cell based assays, high content analysis and cell screening. We develop, manufacture, and distribute products that make cellular analysis robust an more

All websites on qiagen
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE